Last reviewed · How we verify
Pilocarpine Nitrate 5%
Pilocarpine Nitrate 5% is a Small molecule drug developed by Richard Barry Moss. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pilocarpine Nitrate 5% |
|---|---|
| Sponsor | Richard Barry Moss |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function (NA)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty (NA)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial (NA)
- A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age (PHASE3)
- Gender Differences in Renal Functioning and Disease
- Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS) (NA)
- Morphological Changes of Ciliary Body and Trabecular Meshwork (NA)
- Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pilocarpine Nitrate 5% CI brief — competitive landscape report
- Pilocarpine Nitrate 5% updates RSS · CI watch RSS
- Richard Barry Moss portfolio CI
Frequently asked questions about Pilocarpine Nitrate 5%
What is Pilocarpine Nitrate 5%?
Who makes Pilocarpine Nitrate 5%?
What development phase is Pilocarpine Nitrate 5% in?
Related
- Manufacturer: Richard Barry Moss — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing